-
1
-
-
33847638137
-
Estimates of the cancer incidence and mortality in Europe in 2006
-
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581-592.
-
(2007)
Ann Oncol
, vol.18
, Issue.3
, pp. 581-592
-
-
Ferlay, J.1
Autier, P.2
Boniol, M.3
Heanue, M.4
Colombet, M.5
Boyle, P.6
-
3
-
-
84861594994
-
Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in nonsmall-cell lung cancer (NSCLC)
-
Reungwetwattana T, Weroha SJ, Molina JR. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in nonsmall-cell lung cancer (NSCLC). Clin Lung Cancer. 2012;13(4): 252-266.
-
(2012)
Clin Lung Cancer
, vol.13
, Issue.4
, pp. 252-266
-
-
Reungwetwattana, T.1
Weroha, S.J.2
Molina, J.R.3
-
4
-
-
77954321859
-
Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
-
D'Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21(Suppl 5):116-119.
-
(2010)
Ann Oncol
, vol.21
, Issue.SUPPL. 5
, pp. 116-119
-
-
D'Addario, G.1
Fruh, M.2
Reck, M.3
Baumann, P.4
Klepetko, W.5
Felip, E.6
-
5
-
-
18144392737
-
Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer: A realistic goal?
-
Blackhall FH, Shepherd FA, Albain KS. Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer: a realistic goal? Treat Respir Med. 2005;4(2):71-84.
-
(2005)
Treat Respir Med
, vol.4
, Issue.2
, pp. 71-84
-
-
Blackhall, F.H.1
Shepherd, F.A.2
Albain, K.S.3
-
6
-
-
69949162760
-
Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10): 947-957.
-
(2009)
N Engl J Med
, vol.361
, Issue.10
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
-
7
-
-
0032999409
-
EGF receptor
-
Wells A. EGF receptor. Int J Biochem Cell Biol. 1999;31(6): 637-643.
-
(1999)
Int J Biochem Cell Biol
, vol.31
, Issue.6
, pp. 637-643
-
-
Wells, A.1
-
8
-
-
0034722889
-
The EGF receptor family as targets for cancer therapy
-
Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19(56):6550-6565.
-
(2000)
Oncogene
, vol.19
, Issue.56
, pp. 6550-6565
-
-
Mendelsohn, J.1
Baselga, J.2
-
9
-
-
34648815009
-
Lung cancer in never smokers - a different disease
-
Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers - a different disease. Nat Rev Cancer. 2007;7(10):778-790.
-
(2007)
Nat Rev Cancer
, vol.7
, Issue.10
, pp. 778-790
-
-
Sun, S.1
Schiller, J.H.2
Gazdar, A.F.3
-
10
-
-
33947502512
-
Lung cancer in never smokers: A review
-
Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007;25(5):561-570.
-
(2007)
J Clin Oncol
, vol.25
, Issue.5
, pp. 561-570
-
-
Subramanian, J.1
Govindan, R.2
-
11
-
-
42549089715
-
Lung adenocarcinoma: Guiding EGFR-targeted therapy and beyond
-
Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008;21(Suppl 2):S16-S22.
-
(2008)
Mod Pathol
, vol.21
, Issue.SUPPL. 2
-
-
Ladanyi, M.1
Pao, W.2
-
12
-
-
0037025173
-
Cancer. Addiction to oncogenes - the Achilles heal of cancer
-
Weinstein IB. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science. 2002;297(5578):63-64.
-
(2002)
Science
, vol.297
, Issue.5578
, pp. 63-64
-
-
Weinstein, I.B.1
-
13
-
-
41649102043
-
The cancer biomarker problem
-
Sawyers CL. The cancer biomarker problem. Nature. 2008;452(7187): 548-552.
-
(2008)
Nature
, vol.452
, Issue.7187
, pp. 548-552
-
-
Sawyers, C.L.1
-
14
-
-
75249087060
-
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial
-
Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121-128.
-
(2010)
Lancet Oncol
, vol.11
, Issue.2
, pp. 121-128
-
-
Mitsudomi, T.1
Morita, S.2
Yatabe, Y.3
-
15
-
-
77953930730
-
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
-
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-2388.
-
(2010)
N Engl J Med
, vol.362
, Issue.25
, pp. 2380-2388
-
-
Maemondo, M.1
Inoue, A.2
Kobayashi, K.3
-
16
-
-
79960889662
-
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised phase 3 study
-
Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised phase 3 study. Lancet Oncol. 2011;12(8): 735-742.
-
(2011)
Lancet Oncol
, vol.12
, Issue.8
, pp. 735-742
-
-
Zhou, C.1
Wu, Y.L.2
Chen, G.3
-
17
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
-
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-246.
-
(2012)
Lancet Oncol
, vol.13
, Issue.3
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
-
18
-
-
77958478674
-
Rational, biologically based treatment of EGFRmutant non-small-cell lung cancer
-
Pao W, Chmielecki J. Rational, biologically based treatment of EGFRmutant non-small-cell lung cancer. Nat Rev Cancer. 2010;10(11): 760-774.
-
(2010)
Nat Rev Cancer
, vol.10
, Issue.11
, pp. 760-774
-
-
Pao, W.1
Chmielecki, J.2
-
19
-
-
34249075147
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
-
Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039-1043.
-
(2007)
Science
, vol.316
, Issue.5827
, pp. 1039-1043
-
-
Engelman, J.A.1
Zejnullahu, K.2
Mitsudomi, T.3
-
20
-
-
0033763084
-
ZD1839 ("Iressa") as an anticancer agent
-
Baselga J, Averbuch SD. ZD1839 ("Iressa") as an anticancer agent. Drugs. 2000;60(Suppl 1):33-40.
-
(2000)
Drugs
, vol.60
, Issue.SUPPL. 1
, pp. 33-40
-
-
Baselga, J.1
Averbuch, S.D.2
-
21
-
-
84861976809
-
First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung
-
Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122-1128.
-
(2012)
J Clin Oncol
, vol.30
, Issue.10
, pp. 1122-1128
-
-
Han, J.Y.1
Park, K.2
Kim, S.W.3
-
22
-
-
77649203360
-
Randomized phase III trial of platinumdoublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: Results of a West Japan Thoracic Oncology Group trial (WJTOG0203)
-
Takeda K, Hida T, Sato T, et al. Randomized phase III trial of platinumdoublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a West Japan Thoracic Oncology Group trial (WJTOG0203). J Clin Oncol. 2010;28(5):753-760.
-
(2010)
J Clin Oncol
, vol.28
, Issue.5
, pp. 753-760
-
-
Takeda, K.1
Hida, T.2
Sato, T.3
-
23
-
-
84860479704
-
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): A multicentre, double-blind randomised phase 3 trial
-
Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 2012;13(5):466-475.
-
(2012)
Lancet Oncol
, vol.13
, Issue.5
, pp. 466-475
-
-
Zhang, L.1
Ma, S.2
Song, X.3
-
24
-
-
56249109644
-
Gefitinib vs docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial
-
Kim ES, Hirsh V, Mok T, et al. Gefitinib vs docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809-1818.
-
(2008)
Lancet
, vol.372
, Issue.9652
, pp. 1809-1818
-
-
Kim, E.S.1
Hirsh, V.2
Mok, T.3
-
25
-
-
77954425780
-
Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients
-
Yamamoto N, Nishiwaki Y, Negoro S, et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients. J Thorac Oncol. 2010;5(7):1042-1047.
-
(2010)
J Thorac Oncol
, vol.5
, Issue.7
, pp. 1042-1047
-
-
Yamamoto, N.1
Nishiwaki, Y.2
Negoro, S.3
-
26
-
-
76749154617
-
Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy
-
Lee DH, Park K, Kim JH, et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res. 2010;16(4):1307-1314.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.4
, pp. 1307-1314
-
-
Lee, D.H.1
Park, K.2
Kim, J.H.3
-
27
-
-
33646867322
-
SIGN Study Group. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
-
Cufer T
-
Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K; SIGN Study Group. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs. 2006;17(4):401-409.
-
(2006)
Anticancer Drugs
, vol.17
, Issue.4
, pp. 401-409
-
-
Cufer, T.1
Vrdoljak, E.2
Gaafar, R.3
Erensoy, I.4
Pemberton, K.5
-
28
-
-
27544503230
-
Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
-
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527-1537.
-
(2005)
Lancet
, vol.366
, Issue.9496
, pp. 1527-1537
-
-
Thatcher, N.1
Chang, A.2
Parikh, P.3
-
29
-
-
1542503746
-
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1
-
Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol. 2004;22(5):777-784.
-
(2004)
J Clin Oncol
, vol.22
, Issue.5
, pp. 777-784
-
-
Giaccone, G.1
Herbst, R.S.2
Manegold, C.3
-
30
-
-
1542713370
-
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
-
Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol. 2004;22(5):785-794.
-
(2004)
J Clin Oncol
, vol.22
, Issue.5
, pp. 785-794
-
-
Herbst, R.S.1
Giaccone, G.2
Schiller, J.H.3
-
31
-
-
42449109047
-
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older
-
Simon GR, Extermann M, Chiappori A, et al. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008;112(9):2021-2029.
-
(2008)
Cancer
, vol.112
, Issue.9
, pp. 2021-2029
-
-
Simon, G.R.1
Extermann, M.2
Chiappori, A.3
-
32
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132.
-
(2005)
N Engl J Med
, vol.353
, Issue.2
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues, P.J.2
Ciuleanu, T.3
-
33
-
-
69949186250
-
Screening for epidermal growth factor receptor mutations in lung cancer
-
Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10): 958-967.
-
(2009)
N Engl J Med
, vol.361
, Issue.10
, pp. 958-967
-
-
Rosell, R.1
Moran, T.2
Queralt, C.3
-
34
-
-
84868192444
-
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): A double-blind, placebo-controlled, phase 3 trial
-
Lee SM, Khan I, Upadhyay S, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2012;13(11):1161-1170.
-
(2012)
Lancet Oncol
, vol.13
, Issue.11
, pp. 1161-1170
-
-
Lee, S.M.1
Khan, I.2
Upadhyay, S.3
-
35
-
-
24944440830
-
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
-
Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(25):5892-5899.
-
(2005)
J Clin Oncol
, vol.23
, Issue.25
, pp. 5892-5899
-
-
Herbst, R.S.1
Prager, D.2
Hermann, R.3
-
36
-
-
34248140107
-
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
-
Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25(12):1545-1552.
-
(2007)
J Clin Oncol
, vol.25
, Issue.12
, pp. 1545-1552
-
-
Gatzemeier, U.1
Pluzanska, A.2
Szczesna, A.3
-
37
-
-
84863011008
-
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
-
Coudert B, Ciuleanu T, Park K, et al. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol. 2012;23(2):388-394.
-
(2012)
Ann Oncol
, vol.23
, Issue.2
, pp. 388-394
-
-
Coudert, B.1
Ciuleanu, T.2
Park, K.3
-
38
-
-
70349477817
-
ATLAS Investigators. A randomized, double-blind, placebo controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastasic non-small cell lung cancer [abstract]
-
Miller VA, O'Connor P, Soh C, et al; ATLAS Investigators. A randomized, double-blind, placebo controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastasic non-small cell lung cancer [abstract]. J Clin Oncol. 2009;27(Suppl 18):LBA8002.
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL. 18
-
-
Miller, V.A.1
O'Connor, P.2
Soh, C.3
-
39
-
-
84867059528
-
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer
-
Perol M, Chouaid C, Perol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012;30(28):3516-3524.
-
(2012)
J Clin Oncol
, vol.30
, Issue.28
, pp. 3516-3524
-
-
Perol, M.1
Chouaid, C.2
Perol, D.3
-
40
-
-
84865154870
-
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced nonsmall-cell lung cancer: The TORCH randomized trial
-
Gridelli C, Ciardiello F, Gallo C, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced nonsmall-cell lung cancer: the TORCH randomized trial. J Clin Oncol. 2012;30(24):3002-3011.
-
(2012)
J Clin Oncol
, vol.30
, Issue.24
, pp. 3002-3011
-
-
Gridelli, C.1
Ciardiello, F.2
Gallo, C.3
-
41
-
-
84857501696
-
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study
-
Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13(3):300-308.
-
(2012)
Lancet Oncol
, vol.13
, Issue.3
, pp. 300-308
-
-
Ciuleanu, T.1
Stelmakh, L.2
Cicenas, S.3
-
42
-
-
84875632711
-
Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: A phase II study (CTONG-0803)
-
November 4, 2012, Epub ahead of print
-
Wu YL, Zhou C, Cheng Y, et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol. November 4, 2012. [Epub ahead of print.]
-
Ann Oncol
-
-
Wu, Y.L.1
Zhou, C.2
Cheng, Y.3
-
43
-
-
33750302365
-
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib
-
Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res. 2006;12(19): 5764-5769.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.19
, pp. 5764-5769
-
-
Kosaka, T.1
Yatabe, Y.2
Endoh, H.3
-
44
-
-
33749824425
-
Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients
-
Tamborini E, Pricl S, Negri T, et al. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene. 2006;25(45): 6140-6146.
-
(2006)
Oncogene
, vol.25
, Issue.45
, pp. 6140-6146
-
-
Tamborini, E.1
Pricl, S.2
Negri, T.3
-
45
-
-
40049099220
-
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
-
Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008;105(6):2070-2075.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, Issue.6
, pp. 2070-2075
-
-
Yun, C.H.1
Mengwasser, K.E.2
Toms, A.V.3
-
46
-
-
79960085862
-
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling
-
Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011;3(90):90ra59.
-
(2011)
Sci Transl Med
, vol.3
, Issue.90
-
-
Chmielecki, J.1
Foo, J.2
Oxnard, G.R.3
-
47
-
-
84863410315
-
EGFR-TKI resistant non-small cell lung cancer (NSCLC): New developments and implications for future treatment
-
Brugger W, Thomas M. EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment. Lung Cancer. 2012;77(1):2-8.
-
(2012)
Lung Cancer
, vol.77
, Issue.1
, pp. 2-8
-
-
Brugger, W.1
Thomas, M.2
-
48
-
-
84862819699
-
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
-
Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012;13(5):539-548.
-
(2012)
Lancet Oncol
, vol.13
, Issue.5
, pp. 539-548
-
-
Yang, J.C.1
Shih, J.Y.2
Su, W.C.3
-
49
-
-
83455209248
-
A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN) [abstract]
-
Sun Y, Shi Y, Zhang L, et al. A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN) [abstract]. J Clin Oncol. 2011;29 Suppl:7522.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
, pp. 7522
-
-
Sun, Y.1
Shi, Y.2
Zhang, L.3
-
50
-
-
56749102822
-
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as firstline treatment for advanced non-small-cell lung cancer
-
Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as firstline treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008;26(33):5407-5415.
-
(2008)
J Clin Oncol
, vol.26
, Issue.33
, pp. 5407-5415
-
-
Heymach, J.V.1
Paz-Ares, L.2
de Braud, F.3
-
51
-
-
77954035012
-
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial
-
Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010;11(7):619-626.
-
(2010)
Lancet Oncol
, vol.11
, Issue.7
, pp. 619-626
-
-
Herbst, R.S.1
Sun, Y.2
Eberhardt, W.E.3
-
52
-
-
84861720010
-
Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: A randomized, double-blind phase III trial (ZEPHYR)
-
Lee JS, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol. 2012;30(10): 1114-1121.
-
(2012)
J Clin Oncol
, vol.30
, Issue.10
, pp. 1114-1121
-
-
Lee, J.S.1
Hirsh, V.2
Park, K.3
-
53
-
-
79952748468
-
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer
-
Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(8):1059-1066.
-
(2011)
J Clin Oncol
, vol.29
, Issue.8
, pp. 1059-1066
-
-
Natale, R.B.1
Thongprasert, S.2
Greco, F.A.3
-
54
-
-
84866255620
-
Randomized phase II study of dacomitinib (PF-00299804), an irreversible panhuman epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer
-
Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible panhuman epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012;30(27):3337-3344.
-
(2012)
J Clin Oncol
, vol.30
, Issue.27
, pp. 3337-3344
-
-
Ramalingam, S.S.1
Blackhall, F.2
Krzakowski, M.3
-
55
-
-
84655160812
-
XL647 - a multitargeted tyrosine kinase inhibitor: Results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib
-
Pietanza MC, Lynch TJ Jr, Lara PN Jr, et al. XL647 - a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol. 2012;7(1): 219-226.
-
(2012)
J Thorac Oncol
, vol.7
, Issue.1
, pp. 219-226
-
-
Pietanza, M.C.1
Lynch Jr., T.J.2
Lara Jr., P.N.3
-
56
-
-
34249093653
-
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer
-
Adjei AA, Molina JR, Mandrekar SJ, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res. 2007;13(9): 2684-2691.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.9
, pp. 2684-2691
-
-
Adjei, A.A.1
Molina, J.R.2
Mandrekar, S.J.3
-
57
-
-
77958161544
-
Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer
-
Price KA, Azzoli CG, Krug LM, et al. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(10):1623-1629.
-
(2010)
J Thorac Oncol
, vol.5
, Issue.10
, pp. 1623-1629
-
-
Price, K.A.1
Azzoli, C.G.2
Krug, L.M.3
-
58
-
-
79952714380
-
A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer
-
Han JY, Lee SH, Yoo NJ, et al. A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2011;17(6):1553-1560.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.6
, pp. 1553-1560
-
-
Han, J.Y.1
Lee, S.H.2
Yoo, N.J.3
-
59
-
-
0041816104
-
Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor
-
Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003;278(37):35451-35457.
-
(2003)
J Biol Chem
, vol.278
, Issue.37
, pp. 35451-35457
-
-
Buchanan, F.G.1
Wang, D.2
Bargiacchi, F.3
Dubois, R.N.4
-
60
-
-
41749124798
-
Gefitinib plus celecoxib in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: A phase II study from the Hoosier Oncology Group
-
Agarwala A, Fisher W, Bruetman D, et al. Gefitinib plus celecoxib in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. J Thorac Oncol. 2008;3(4):374-379.
-
(2008)
J Thorac Oncol
, vol.3
, Issue.4
, pp. 374-379
-
-
Agarwala, A.1
Fisher, W.2
Bruetman, D.3
-
61
-
-
79959306917
-
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer
-
Spigel DR, Burris HA 3rd, Greco FA, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(18):2582-2589.
-
(2011)
J Clin Oncol
, vol.29
, Issue.18
, pp. 2582-2589
-
-
Spigel, D.R.1
Burris III, H.A.2
Greco, F.A.3
-
62
-
-
79959695837
-
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: A randomized phase II study
-
Gridelli C, Morgillo F, Favaretto A, et al. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Ann Oncol. 2011;22(7):1528-1534.
-
(2011)
Ann Oncol
, vol.22
, Issue.7
, pp. 1528-1534
-
-
Gridelli, C.1
Morgillo, F.2
Favaretto, A.3
-
63
-
-
84863936062
-
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial
-
Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol. 2012;30(17):2070-2078.
-
(2012)
J Clin Oncol
, vol.30
, Issue.17
, pp. 2070-2078
-
-
Scagliotti, G.V.1
Krzakowski, M.2
Szczesna, A.3
-
64
-
-
77955503066
-
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer
-
Altorki N, Lane ME, Bauer T, et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol. 2010;28(19): 3131-3137.
-
(2010)
J Clin Oncol
, vol.28
, Issue.19
, pp. 3131-3137
-
-
Altorki, N.1
Lane, M.E.2
Bauer, T.3
-
65
-
-
84878546364
-
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib
-
November 8, 2012, Epub ahead of print
-
Dy GK, Infante JR, Eckhardt SG, et al. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib. Invest New Drugs. November 8, 2012. [Epub ahead of print.]
-
Invest New Drugs
-
-
Dy, G.K.1
Infante, J.R.2
Eckhardt, S.G.3
-
66
-
-
80051974548
-
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer
-
Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 2011;29(24): 3307-3315.
-
(2011)
J Clin Oncol
, vol.29
, Issue.24
, pp. 3307-3315
-
-
Sequist, L.V.1
von Pawel, J.2
Garmey, E.G.3
-
67
-
-
84878570861
-
Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract]
-
Ou SH, Govindan R, Eaton KD, et al. Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2012;30 Suppl:2610.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
, pp. 2610
-
-
Ou, S.H.1
Govindan, R.2
Eaton, K.D.3
-
68
-
-
84868301289
-
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)
-
Zappa F, Droege C, Betticher D, et al. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer. 2012;78(3):239-244.
-
(2012)
Lung Cancer
, vol.78
, Issue.3
, pp. 239-244
-
-
Zappa, F.1
Droege, C.2
Betticher, D.3
-
69
-
-
79957823572
-
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A double-blind, placebo-controlled, phase 3 trial
-
Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011;377(9780): 1846-1854.
-
(2011)
Lancet
, vol.377
, Issue.9780
, pp. 1846-1854
-
-
Herbst, R.S.1
Ansari, R.2
Bustin, F.3
-
70
-
-
84878530756
-
Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77
-
October 24, 2012, Epub ahead of print
-
Riggs H, Jalal SI, Baghdadi TA, et al. Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77. Clin Lung Cancer. October 24, 2012. [Epub ahead of print.]
-
Clin Lung Cancer
-
-
Riggs, H.1
Jalal, S.I.2
Baghdadi, T.A.3
-
71
-
-
84878537950
-
Efficacy and safety of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy [abstract]
-
Smith DA, Conkling P, Richards DA, et al. Efficacy and safety of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy [abstract]. J Clin Oncol. 2012;30 Suppl: e18047.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Smith, D.A.1
Conkling, P.2
Richards, D.A.3
-
72
-
-
84858334156
-
A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer
-
Weickhardt A, Doebele R, Oton A, et al. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2012;7(2): 419-426.
-
(2012)
J Thorac Oncol
, vol.7
, Issue.2
, pp. 419-426
-
-
Weickhardt, A.1
Doebele, R.2
Oton, A.3
-
73
-
-
83355174075
-
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer
-
Ramalingam SS, Spigel DR, Chen D, et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol. 2011;29(34):4574-4580.
-
(2011)
J Clin Oncol
, vol.29
, Issue.34
, pp. 4574-4580
-
-
Ramalingam, S.S.1
Spigel, D.R.2
Chen, D.3
-
74
-
-
84866596876
-
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer
-
Papadimitrakopoulou VA, Soria JC, Jappe A, Jehl V, Klimovsky J, Johnson BE. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol. 2012;7(10):1594-1601.
-
(2012)
J Thorac Oncol
, vol.7
, Issue.10
, pp. 1594-1601
-
-
Papadimitrakopoulou, V.A.1
Soria, J.C.2
Jappe, A.3
Jehl, V.4
Klimovsky, J.5
Johnson, B.E.6
-
75
-
-
84866154541
-
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer
-
Clement-Duchene C, Natale RB, Jahan T, et al. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. Lung Cancer. 2012;78(1): 57-62.
-
(2012)
Lung Cancer
, vol.78
, Issue.1
, pp. 57-62
-
-
Clement-Duchene, C.1
Natale, R.B.2
Jahan, T.3
-
76
-
-
68349122406
-
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer
-
Lynch TJ, Fenton D, Hirsh V, et al. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2009;4(8): 1002-1009.
-
(2009)
J Thorac Oncol
, vol.4
, Issue.8
, pp. 1002-1009
-
-
Lynch, T.J.1
Fenton, D.2
Hirsh, V.3
-
77
-
-
84864004796
-
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced nonsmall-cell lung cancer who progressed on prior chemotherapy
-
Witta SE, Jotte RM, Konduri K, et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced nonsmall-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 2012;30(18):2248-2255.
-
(2012)
J Clin Oncol
, vol.30
, Issue.18
, pp. 2248-2255
-
-
Witta, S.E.1
Jotte, R.M.2
Konduri, K.3
-
78
-
-
80052441453
-
Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib [abstract]
-
Janjigian YY, Groen HJ, Horn L, et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib [abstract]. J Clin Oncol. 2011; 29 Suppl:7525.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
, pp. 7525
-
-
Janjigian, Y.Y.1
Groen, H.J.2
Horn, L.3
-
79
-
-
49649127657
-
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
-
Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2008;14(10):2895-2899.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.10
, pp. 2895-2899
-
-
Engelman, J.A.1
Janne, P.A.2
|